President Trump, alongside the CEOs of Pfizer and AstraZeneca, announced new agreements to significantly lower prescription drug prices for Americans. These changes aim to ensure that drug prices align more closely with what other countries pay.
• Pfizer is set to discount its drugs in the U. S. by 50 to 100 percent.
• Under a new policy called Most Favored Nation (MFN), new Pfizer medications will be priced at levels comparable to other countries.
• AstraZeneca has also joined the agreement, committing to major discounts and adopting MFN pricing.
• Trump highlighted potential reductions, such as a 654 percent decrease for specific drugs, particularly for respiratory and diabetic medications.
• Americans can find these lower-priced medications through a new website, TrumpRx.gov.
• The agreements will also save American taxpayers hundreds of millions annually, especially for Medicaid patients.
• AstraZeneca plans to invest $50 billion in the U. S. over five years for drug research and manufacturing.
• Virginia Governor Glenn Youngkin described the deal as a significant win for Americans regarding fair medication access.
These initiatives mark a critical step towards improving prescription drug affordability for American patients, aiming to bring prices in line with global standards. Further updates on this developing story will follow.
No comments:
Post a Comment